Correlation between mammographic calcifications and HER-2/neu overexpression in breast carcinoma
Author:
Affiliation:
Fund Project:
摘要
|
图/表
|
访问统计
|
参考文献
|
相似文献
|
引证文献
|
资源附件
|
音频文件
|
视频文件
摘要:
目的:探讨乳腺癌钼靶X线钙化与HER-2/neu表达的关系及其临床意义。 方法:分析152例乳腺癌钼靶X线片的钙化特点;并将切除的肿瘤标本行HER-2/neu检测,分析钼靶X线钙化特征与HER-2/neu表达之间的关系。结果:乳腺癌钼靶X线钙化组HER-2/neu过度表达率高于无钙化组(61.6% vs. 35.4%)(P<0.01);在73例钙化中,以钙化伴随毛刺征为主要表现者,HER-2/neu过度表达率高于单纯钙化组(P<0.05)。根据钙化形态特征,蠕虫状钙化组HER-2/neu过度表达率明显高于非蠕虫状钙化组(P=0.01)。钼靶X线钙化簇最大径≥25 mm者,多在HER-2/neu过度表达组(P<0.05),而钙化颗粒数≤20枚/cm2者,多在HER-2/neu阴性表达组(P<0.01)。 结论:乳腺癌钼靶X线钙化与HER-2/neu过度表达关系密切,可为乳腺癌治疗策略的制定和预测预后提供参考。
Abstract:
Abstract:Objective:To evaluate the correlation between mammographic calcifications and HER-2/neu overexpression in breast carcinomas (BC) and its clinical significance. Methods :A retrospective study of preoperative mammograms in patients with breast carcinoma, and immunohistochemical staining of excised tumor specimens was carried out by using monoclonal antibody against HER-2/neu in 152 patients with BC to evaluate the correlation of mammographic calcifications with HER-2/neu overexpression. Results:There was a significant correlation between mammographic calcifications and HER-2/neu overexpression (P<0.01). In the 73 cases of carcinoma with calcifications on mammography, HER-2/neu overexpression was statistically higher in calcifications associated spiculated mass than in simple calcifications (P<0.05). According to morphologic aspects of calcifications, vermicular calcifications were more common in carcinomas with HER-2/neu overexpression than in those without HER-2/neu overexpression (P=0.01). The carcinomas with calcifications ≥25 mm in diameter were much more commonly associated with HER-2/neu overexpression (P<0.05), whereas the number of calcifications less than 20/cm2 was more common in HER-2/neu negative expression (P<0.01). Conclusions:Mammographic calcifications are significantly correlated with HER-2/neu overexpression and may offer reference for planning a therapeutic stategy and predicting prognosis of breast cancer.